Chimeric Therapeutics (ASX:CHM) has achieved a significant regulatory milestone, announcing it has secured FDA Orphan Drug Designation for its lead candidate, CHM CDH17, in the treatment of gastric cancer. …
Chimeric secures key orphan drug designation, paving the way for accelerated development
December 8, 2025 Australian Biotech
Latest Video
New Stories
-
The 'Dispatched' Podcast - Week in review
August 7, 2026 - - Podcast -
argenx partners with Monash University and Myostellar to develop muscular therapies
August 7, 2026 - - Latest News -
A new generation is rewriting their lives living with Cystic Fibrosis
August 7, 2026 - - Latest News -
US approves Moderna's mRNA flu vaccine in major technology milestone
August 7, 2026 - - Latest News -
If Australian companies shun their domestic market, who can blame multinationals?
August 6, 2026 - - Latest News -
Neuren reports record DAYBUE sales as royalties rise and global expansion nears
August 6, 2026 - - Australian Biotech -
Moderna begins Phase 1 trial of vaccine candidate against Bundibugyo Ebola Virus
August 6, 2026 - - Latest News